MRNA at $150+ — who’s still shorting this, and who thinks the squeeze has more room?

{"summary": "Author is short Moderna, arguing the post-Phase-3 melanoma rally overprices a single cancer indication and was partly driven by a short/gamma squeeze.", "reason": "The author provides a clear directional position (short), a fundamental valuation rationale (market overreaction to melanoma data), and a verbatim quote supporting the position.", "ideas": [{"symbol": "MRNA", "direction": "short", "thesis": "The author has been building and adding to a short position in Moderna since roughly $140, arguing the market massively overreacted to positive Phase 3 melanoma data. The mechanism is valuation: even treating a very large share of eligible melanoma patients would not justify the post-announcement market cap, so the price requires believing Moderna becomes a much broader oncology platform. The author notes short interest was already around 15% of float before the move, suggesting part of the rally was short/gamma squeeze dynamics rather than fundamental repricing. Main risk implied is a continued squeeze or a broader oncology platform materializing, pushing the stock toward $180-200+.", "thesis_short": "Short MRNA; melanoma data overpriced, squeeze-driven rally", "quote": "I’ve been building a short position in Moderna since roughly $140 and adding as the stock moved higher.", "confidence": 0.85, "sentiment": -0.7, "timeframe": "unspecified"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}